DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fj8n85/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020" report to their offering.
The approval of Rituxan (rituximab) has caused the size of the Non-Hodgkin Lymphoma (NHL) market to increase dramatically over the last two decades.
This growth is expected to continue at a moderate pace during the forecast period, from $5.6 billion in 2013 culminating in revenues of $9.2 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.4%, in the major developed markets.
In 2013, the major share of the global NHL market was attributed to by the US, representing 53% of the overall NHL market and this dominance is expected to be retained throughout the forecast period.
The increasing uptake of new targeted therapies, especially novel small molecule inhibitors in the relapsed and refractory setting, along with the dominant usage of Rituxan is expected to fuel market growth in all the major developed markets. The expected launches of premium-priced novel antibodies and small molecule inhibitors, especially protein kinase inhibitors, targeting both indolent and aggressive sub-types of NHLs will widen the treatment population eligible for novel targeted and immunotherapies.
The anticipated approval of promising pipeline drug candidates, Roche's obinutuzumab, Novartis' Afinitor (everolimus), Takeda's alisertib and Biovest's BiovaxID (dasiprotimut T) and GlaxoSmithKline's Arzerra (ofatumumab) for various NHL subtypes is a key driver for the steady increase in NHL market size. Despite of a flurry of expected launches, the growth in market is not anticipated to grow rapidly, particularly due to loss of patent exclusivity of Rituxan during the forecast period.
Recently Launched Targeted and Immunotherapies has Widened Treatment Alternatives for Specific Sub-types
Over the past two decades, significant progress has been made in the development of new therapies for NHL. Perhaps the most important milestone is the addition of Rituxan, approved by the US Food and Drug Administration (FDA) for relapsed or refractory Cluster of Differentiation (CD) 20-positive B-cell lymphoma in 1997.
Following the approval of Rituxan in 1997, the US FDA approved five other monoclonal Antibodies (mAbs): Campath (alemtuzumab) in 2001, Bexxar (tositumomab) in 2003, Zevalin (ibritumomab tiuxetan) in 2002, Arzerra in 2009, and Adcetris (brentuximab vedotin) in 2011. Another novel mAb, mogamulizumab, which is still in Phase III clinical trials in the US, has already gained approval in Japan. The majority of these drugs are approved for the treatment of specific NHL sub-types.
Key Topics Covered:
1 Tables & Figures
3 Marketed Products
4 Pipeline Products
5 Market Forecast to 2020
6 Deals and Strategic Consolidations
For more information visit http://www.researchandmarkets.com/research/fj8n85/nonhodgkin